One Patient's lifeline: donor t cells take on EBV lymphoma
NCT ID NCT06391814
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a personalized treatment for a young adult with a severe EBV-related lymphoma that occurred after a stem cell transplant. The patient received up to four infusions of specially grown immune cells from their original stem cell donor. The goal was to see if these cells could safely control the lymphoma and improve the body's ability to fight the virus.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- EBV-specific T cells (donor-derived immune cells)
- What this could lead to
- If successful, this approach could offer a way to control EBV-related lymphoma after a stem cell transplant without causing severe graft-versus-host disease.
- What could go wrong
- This was a single-patient study, so results may not apply to others. The treatment carries risks like graft-versus-host disease or infection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBV ASSOCIATED LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ciusss-Emtl
Montreal, Quebec, H1T 2M4, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.